1. Home
  2. Clinical Topics
  3. Cardio-Pulmonary
  4. FDA approves Belviq for treatment of obesity
Cardio-PulmonaryClinical TopicsDrugs and DevicesEndocrinologyNewsWeb Exclusives

FDA approves Belviq for treatment of obesity

Share

On June 27, the U.S. Food and Drug Administration approved Belviq (lorcaserin hydrochloride) for the treatment of obesity. It is to be used in combination with a reduced-calorie diet and exercise for chronic weight management. The drug is approved for use in adults with a body mass index (BMI) of 30 or greater (obese), or adults with a BMI of 27 or greater (overweight) and who have at least one weight-related condition such as hypertension, type 2 diabetes, or dyslipidemia. Read more.

Leave a Reply

Your email address will not be published.

Fill out this field
Fill out this field
Please enter a valid email address.

cheryl meeGet your free access to the exclusive newsletter of American Nurse Journal and gain insights for your nursing practice.

NurseLine Newsletter

  • Hidden

*By submitting your e-mail, you are opting in to receiving information from Healthcom Media and Affiliates. The details, including your email address/mobile number, may be used to keep you informed about future products and services.

Recent Posts